AB Sciex to Drive Innovation in Separations Science with Combination of Eksigent Chromatography with Capillary Electrophoresis from Beckman Coulter Life Sciences
FRAMINGHAM, Mass. – July 10, 2013 – AB Sciex Pte. Ltd., a global leader in analytical technologies, today announced the combination of its chromatography business with the capillary electrophoresis (CE) business from Beckman Coulter Life Sciences, an innovator in life science research, to advance separations science. This move brings together Beckman Coulter’s expertise in microscale separation with the expertise in microfluidics of the Eksigent chromatography team of AB Sciex.
This combination includes the transition of personnel as well as CE technologies and resources from Beckman Coulter Life Sciences to AB Sciex ‒ two leading life science companies that are both owned by Danaher Corporation, a leader in science and technology. This new alignment will lead to better serving customers while addressing analytical challenges with powerful scientific strategies that take advantage of complementary technologies.
“We are bringing together the best in CE with the best in nano LC and micro LC as a unified team to broaden the range of solutions available to our customers,” said Rainer Blair, President of AB Sciex. “By integrating the Beckman Coulter CE team into the Sciex separations business, we will be able to take CE and our chromatography solutions to a whole new level. We are committed to investing in our separations business for long-term success.”
The Eksigent LC team of the Sciex separations business and the CE team of Beckman Coulter, a leader in benchtop capillary electrophoresis, will work together going forward to develop breakthrough, integrated applications that provide fast and efficient separations of drugs, drug metabolites, organic acids, amino acids, low molecular weight amines, peptides, nucleic acids and nucleosides.
The new alignment within the Sciex separations business will also unlock greater potential to extend technology leadership, synergies and market presence. This will contribute to the advancement of biologics, clinical research and academic research for biological applications.
Among the synergies is the combination of CE technology and mass spectrometry (MS) technology. CE-MS allows researchers to expand the range of analytes detected while improving overall assay sensitivity. The selectivity of CE in front-end separation further enables the characterization of intact proteins, their isoforms, cleaved fragments and complexes. CE-MS provides information that is complementary to nano LC for proteomics research.
By the end of Q3, the Sciex separations business will manage both the standalone Beckman Coulter CE products and the integrated CE-MS technology. The CE products will continue to be branded ‘Beckman Coulter.’ The separations business will also continue to manage all chromatography products, including Eksigent nano LC and micro LC systems, chips, software and columns.
About Beckman Coulter
Life Sciences Beckman Coulter Life Sciences is dedicated to improving the health of people around the world. The company’s global leadership and world-class service and support delivers sophisticated instrument systems, reagents and services to life science researchers in academic and commercial laboratories, enabling new discoveries in biology-based research and development. A leader in centrifugation and flow cytometry, Beckman Coulter has long been an innovator in capillary electrophoresis, particle characterization and laboratory automation, and its products are used at the forefront of important areas of investigation, including genomics and proteomics. For more information, please visit www.beckmancoulter.com.